Establishment of a patient-derived drug-resistant oral squamous cell carcinoma animal model.

ABSTRACT: Oral squamous cell carcinoma (OSCC) constitutes 90% of oral tumors. Advanced cases severely impair patients' life quality of life due to anatomical location and limited therapies. Conventional treatments often induce drug resistance or recurrence. Patient-derived xenograft (PDX) models are widely used to simulate tumor progression and drug responses, serving as translational tools for precision medicine. This study aimed to establish drug-resistant OSCC PDX models. Human OSCC tissues were transplanted into immunodeficient mice and passaged (P1-P2). At P2 (tumor volume: 40-80 mm³), mice received cisplatin (1 mg/kg, three times/week) with cetuximab (1 mg/kg, weekly), GSK690693 (10 mg/kg, five times/week), or rapamycin (4 mg/kg, five times/week). PDX tissues from groups with less-t

SUBMITTER: Feng C 

PROVIDER: S-EPMC12464870 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature